scholarly journals Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing

Oncotarget ◽  
2014 ◽  
Vol 5 (10) ◽  
pp. 3012-3022 ◽  
Author(s):  
Filip Janku ◽  
Ahmed O. Kaseb ◽  
Apostolia M. Tsimberidou ◽  
Robert A. Wolff ◽  
Razelle Kurzrock
Keyword(s):  
Hepatocellular Carcinoma ◽  
Next Generation Sequencing ◽  
Therapeutic Targets ◽  
Mtor Pathway ◽  
Next Generation ◽  
Targeted Next Generation Sequencing ◽  
Generation Sequencing ◽  
Novel Therapeutic

scholarly journals Using phosphoproteomics and next generation sequencing to discover novel therapeutic targets in patient antibodies

2020 ◽  
Vol 17 (9) ◽  
pp. 675-684
Author(s):  
Lona Zeneyedpour ◽  
Jenny Sten-van `t Hoff ◽  
Theo Luider
Keyword(s):  
Next Generation Sequencing ◽  
Therapeutic Targets ◽  
Next Generation ◽  
Generation Sequencing ◽  
Novel Therapeutic

scholarly journals Qualification of tumour mutational burden by targeted next‐generation sequencing as a biomarker in hepatocellular carcinoma

2020 ◽  
Vol 41 (1) ◽  
pp. 192-203 ◽  
Author(s):  
Ching Ngar Wong ◽  
Petros Fessas ◽  
Kathy Dominy ◽  
Francesco A. Mauri ◽  
Takahiro Kaneko ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Next Generation Sequencing ◽  
Next Generation ◽  
Targeted Next Generation Sequencing ◽  
Mutational Burden ◽  
Generation Sequencing

scholarly journals Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials

2016 ◽  
Vol 26 (4) ◽  
pp. 648-654 ◽  
Author(s):  
Michael L. Friedlander ◽  
Kenneth Russell ◽  
Sherri Millis ◽  
Zoran Gatalica ◽  
Ryan Bender ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Next Generation Sequencing ◽  
Clear Cell ◽  
Therapeutic Targets ◽  
Mtor Pathway ◽  
Receptor Expression ◽  
Next Generation ◽  
Ovarian Cancers ◽  
Response To Chemotherapy ◽  
Generation Sequencing

BackgroundAdvanced stage/recurrent clear cell ovarian cancers (CCOCs) are characterized by a low response to chemotherapy and a poor prognosis. There is growing interest in investigating novel/molecular targeted therapies in patients with CCOC in histotype-specific trials. However, CCOCs are not a uniform entity and comprise a number of molecular subtypes and it is unlikely that a single approach to treatment will be appropriate for all patients. The aim of this study was to analyze the results of a multiplatform profiling panel in CCOCs to identify potential therapeutic targets.Patients and MethodsTumor profiling was performed on 521 CCOCs. They were grouped into pure (n = 422) and mixed (n = 99) CCOC for analysis. Testing included a combination of DNA sequencing (including next-generation sequencing) using a 46-gene panel, immunohistochemistry, fluorescent or chromogenic in situ hybridization, and RNA fragment analysis.ResultsThe most common findings were in the PIK3CA/Akt/mTOR pathway, with 61% of all CCOCs showing a molecular alteration in one of these pathway components. Next-generation sequencing revealed PIK3CA mutations in 50% of pure CCOCs. Significant differences were observed between pure and mixed CCOCs with respect to hormone receptor expression (9% vs 34.7% for ER, 13.45 vs 26.4% for PR), cMET (24.1% vs 11.6%), PD-1 tumor infiltrating lymphocytes (48.1% vs 100%), expression of PD-L1 (7.4% vs 25%), and TOPO1 (41% vs 27.1%) on immunohistochemistry, whereas next-generation sequencing revealed significant differences in mutation frequency in PIK3CA (50% vs 18.5%), TP53 (18.1% vs 57.7%), KRAS (12.4% vs 3.7%), and cMET (1.9% vs 11.1%).ConclusionsThis large study confirms that the PIK3CA/Akt/mTOR pathway is commonly altered in CCOCs, and highlights the significant differences between pure and mixed CCOCs. Clear cell ovarian cancers are molecularly heterogeneous and there are a number of potential therapeutic targets which could be tested in clinical trials.

scholarly journals Targeted Next-Generation Sequencing of Plasma Cell-Free DNA in Korean Patients with Hepatocellular Carcinoma

2021 ◽  
Vol 41 (2) ◽  
pp. 198-206
Author(s):  
Hyojin Chae ◽  
Pil Soo Sung ◽  
Hayoung Choi ◽  
Ahlm Kwon ◽  
Dain Kang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Next Generation Sequencing ◽  
Plasma Cell ◽  
Next Generation ◽  
Cell Free Dna ◽  
Korean Patients ◽  
Targeted Next Generation Sequencing ◽  
Free Dna ◽  
Generation Sequencing

Optimisation and qualification of tumour mutational burden (TMB) by targeted next-generation sequencing (TNGS) as a clinically applicable biomarker in hepatocellular carcinoma (HCC)

2020 ◽  
Vol 73 ◽  
pp. S374-S375
Author(s):  
Ching Ngar Wong ◽  
Kathy Dominy ◽  
Francesco Mauri ◽  
Takahiro Kaneko ◽  
Persephone Du Parcq ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Next Generation Sequencing ◽  
Next Generation ◽  
Targeted Next Generation Sequencing ◽  
Mutational Burden ◽  
Generation Sequencing

scholarly journals Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity

2013 ◽  
Vol 63 (5) ◽  
pp. 920-926 ◽  
Author(s):  
Himisha Beltran ◽  
Roman Yelensky ◽  
Garrett M. Frampton ◽  
Kyung Park ◽  
Sean R. Downing ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Next Generation Sequencing ◽  
Advanced Prostate Cancer ◽  
Therapeutic Targets ◽  
Next Generation ◽  
Disease Heterogeneity ◽  
Targeted Next Generation Sequencing ◽  
Generation Sequencing
Sign in / Sign up

Export Citation Format

Share Document